In the phosphate binder market, the launch of Genzyme's Renvela is beginning to shift market share in both dialysis and CKD segments. While Renvela has primarily cannibalized Renagel share, overall sevelamer share in both dialysis and CKD has increased compared to the prior year. Despite sevelamer's increased share, for the first time, overall satisfaction among the various phosphate binders is highest for Shire's Fosrenol. Concern with lanthanum absorption has fallen in recent quarters and is of significantly less concern than calcium absorption. Both Fresenius Medical Care's PhosLo and calcium carbonate continue to be impacted by concerns with calcium, although calcium binders are expected to remain the preferred agents in CKD. In response to a product profile for ferric citrate (Keryx's Zerenex that is currently in development), interest is high, but this particular compound may have to overcome perceptions of GI tolerability issues.
In the treatment of secondary hyperparathyroidism, Abbott's Zemplar
continues to dominate the Vitamin D market in dialysis with a 74% share. In
the CKD market, calcitriol/Rocaltrol continues to be the leading agent with
42% of the treated patients, and unlike dialysis where brand exclusivity is
common, in CKD less than 5% of Nephrologists prescribe Zemplar or Hectorol
exclusively. The most important PTH Modifier attributes are "Improves
Mortality", "Effectively Lowers PTH", "Supported by Clinical Data", and
"Well-Tolerated". Zemplar and Hectorol receive significantly higher ratings
than Amgen's Sensipar and Calcitriol on "Improves Mortality" and
|SOURCE BioTrends Research Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved